SGP earnings: next report 2026-09-02, real EPS beat/miss history, P/E -19.20. Updated 2026-07-23.
SpyGlass Pharma, Inc. Common Stock (SGP) Research Hub
SpyGlass Pharma, Inc. Common Stock (SGP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 27.52 USD (+0.07%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -19.20, market cap 0.68B. This hub links to the full technical, earnings and options research available for SGP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 27.52 USD (+0.07%) |
| 52-week range | 17.06 USD – 30.05 USD |
| Trend regime | Range |
| 14-day RSI | 63.8 (Bullish) |
| Trailing P/E | -19.20 |
| Market cap | 0.68B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for SGP
Covered Call on SGP: how it works, illustrative setup around the real 27.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SGP: how it works, illustrative setup around the real 27.52 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SGP: how it works, illustrative setup around the real 27.52 USD price, max profit/loss, breakeven and when to use it. Educational.
SGP technical analysis: range, last 27.52 USD, RSI 63.8, 52w range 17.06 USD–30.05 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SGP in?
SpyGlass Pharma, Inc. Common Stock (SGP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SGP in an uptrend or downtrend?
As of 2026-09-11, SGP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SGP's trailing P/E ratio?
SGP's trailing P/E is -19.20, with a market cap of 0.68B. See the earnings research page for full valuation detail.
When does SGP next report earnings?
SGP is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -0.51642 USD.